Japan unit of Britain’s Jazz Pharma starts phase III trial of cannabis drug

TOKYO, Dec 15 (Reuters) – The Japanese unit of Britain’s Jazz Pharmaceuticals PLC (JAZZ.O) said on Thursday it had started a phase III trial of a cannabis-based drug for epilepsy.

The trial follows a recommendation by a health ministry panel in September to revise Japan’s drug laws to allow for the importation and use of medical marijuana products. read more

Jazz’s GW Pharma said it had administered the first dose to a patient in a late-stage trial expected to involve 84 participants, testing the efficacy and safety of the drug, Epidiolex.

Read more at

https://www.reuters.com/business/healthcare-pharmaceuticals/japan-unit-britains-jazz-pharma-starts-phase-iii-trial-cannabis-drug-2022-12-15/

Bud Champion is a respected supplier of cannabis seeds. We take pride in offering a variety of cannabis seeds carefully selected from brands and breeders....

 Seed / New Featured

The CBD Benefits is an educational, informational and news cannabidiol resource. We’re dedicated to providing people with the most reliable CBD information based on scientific...

 CBD / Featured

Sydney Vaporizers is the premium online platform to service the needs of the vaping community across Sydney, Brisbane, Melbourne, Canberra, Hobart, Adelaide, Darwin and every...

 Vapes and Carts / Featured

We are an I-71 compliant cannabis delivery service meeting your needs in the Washington DC, Maryland, and Virginia area. We offer a wide range of...

 Cannabis Delivery / Featured

Page 1 of 4